Multi-Cancer Early Detection Blood Tests: What Galleri Is and Why It's Still Being Studied

What people see in the news

Coverage of "multi-cancer early detection" (MCED) tests — the best-known being Galleri — describes a single blood draw that can screen for many cancers at once, including some with no routine screening test today. It sounds like a breakthrough. The important nuance is that these tests are still being evaluated.

What it actually means

The National Cancer Institute explains that multi-cancer detection tests measure biological signals in body fluids that may be shed by cancer cells — signals also called biomarkers or tumor markers. Depending on which signals a test measures, it may flag several different cancer types from one blood sample. Most MCED tests look for tiny fragments of DNA that tumors can release into the blood (cell-free DNA).

Crucially, NCI states plainly that whether MCED tests are effective for cancer screening in people without symptoms is unknown and needs to be assessed through randomized clinical trials. NCI also notes that no MCED test has been approved by the FDA, although a health care provider may be able to order one.

The largest randomized study so far — the NHS-Galleri trial in the UK, which enrolled roughly 140,000 people — reported its full results in June 2026. The trial did not meet its primary goal: adding the blood test to usual care did not significantly reduce late-stage (stage III and IV) cancer diagnoses overall. Secondary analyses suggested fewer stage IV diagnoses in the screened group, and researchers are continuing to follow participants to see whether the test affects cancer deaths over time. In short: a promising idea with honest, mixed early evidence — which is exactly why careful trials matter.

What this does and doesn't change

For now, these are tests being studied, not established screening tools. To weigh them fairly, it helps to hold the potential benefits and harms side by side:

• Possible benefit: detecting a cancer earlier, sometimes a type with no standard screening test, when treatment might work better.
• Possible harms: false positives (a cancer signal when there's no cancer), which can lead to anxiety and a cascade of follow-up tests; false negatives (a reassuring result when cancer is actually present), which could delay care; and uncertainty about where a signal is coming from. There's also the risk of overdiagnosis — finding a cancer that never would have caused harm.
• These tests are not a replacement for proven screening. Experts stress they should not substitute for recommended mammograms, cervical, colorectal, or lung screening.

The screenings we already know reduce cancer deaths are the ones worth prioritizing, and our free screening check-up tool can help you see which ones apply to you.

Questions to ask a healthcare team

• Is there good evidence this test would benefit someone like me?
• If the result is positive, what follow-up would it require?
• Could this cause me to skip screenings that are proven to work?
• What would a false positive or false negative mean for me?

New technology can be genuinely exciting and still unproven — both can be true at once. Free, plain-language cancer education helps more people ask the right questions before a test, not after.